nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—Nateglinide—Bortezomib—hematologic cancer	0.133	0.258	CrCrCtD
Methamphetamine—Lacosamide—Bortezomib—hematologic cancer	0.126	0.245	CrCrCtD
Methamphetamine—Aspartame—Bortezomib—hematologic cancer	0.126	0.245	CrCrCtD
Methamphetamine—SLC22A3—Melphalan—hematologic cancer	0.106	0.397	CbGbCtD
Methamphetamine—Phenacemide—Vorinostat—hematologic cancer	0.101	0.195	CrCrCtD
Methamphetamine—SLC22A3—Irinotecan—hematologic cancer	0.036	0.134	CbGbCtD
Methamphetamine—SLC22A3—Vincristine—hematologic cancer	0.0315	0.118	CbGbCtD
Methamphetamine—L-Phenylalanine—Melphalan—hematologic cancer	0.0296	0.0574	CrCrCtD
Methamphetamine—CYP2D6—Lomustine—hematologic cancer	0.0177	0.0662	CbGbCtD
Methamphetamine—CYP2D6—Idarubicin—hematologic cancer	0.0158	0.059	CbGbCtD
Methamphetamine—CYP2D6—Hydroxyurea—hematologic cancer	0.0134	0.0502	CbGbCtD
Methamphetamine—CYP2D6—Bortezomib—hematologic cancer	0.0117	0.0436	CbGbCtD
Methamphetamine—CYP2D6—Imatinib—hematologic cancer	0.00857	0.032	CbGbCtD
Methamphetamine—CYP2D6—Nilotinib—hematologic cancer	0.00778	0.029	CbGbCtD
Methamphetamine—CYP2D6—Vinorelbine—hematologic cancer	0.00772	0.0288	CbGbCtD
Methamphetamine—CYP2D6—Vinblastine—hematologic cancer	0.00476	0.0178	CbGbCtD
Methamphetamine—CYP2D6—Dexamethasone—hematologic cancer	0.00352	0.0131	CbGbCtD
Methamphetamine—CYP2D6—Doxorubicin—hematologic cancer	0.00292	0.0109	CbGbCtD
Methamphetamine—TAAR1—lung—hematologic cancer	0.00243	0.0788	CbGeAlD
Methamphetamine—SLC18A1—lymph node—hematologic cancer	0.00177	0.0573	CbGeAlD
Methamphetamine—SLC18A2—hematopoietic system—hematologic cancer	0.00142	0.0461	CbGeAlD
Methamphetamine—SLC6A3—hematopoietic system—hematologic cancer	0.00108	0.0349	CbGeAlD
Methamphetamine—SLC22A3—hematopoietic system—hematologic cancer	0.00101	0.0328	CbGeAlD
Methamphetamine—SLC6A4—hematopoietic system—hematologic cancer	0.000986	0.032	CbGeAlD
Methamphetamine—SLC18A2—blood—hematologic cancer	0.000943	0.0305	CbGeAlD
Methamphetamine—MAOB—hematopoietic system—hematologic cancer	0.000938	0.0304	CbGeAlD
Methamphetamine—SLC18A2—lung—hematologic cancer	0.000827	0.0268	CbGeAlD
Methamphetamine—MAOA—hematopoietic system—hematologic cancer	0.0008	0.0259	CbGeAlD
Methamphetamine—SLC18A2—testis—hematologic cancer	0.00078	0.0253	CbGeAlD
Methamphetamine—SLC22A3—gonad—hematologic cancer	0.000771	0.025	CbGeAlD
Methamphetamine—SLC6A2—gonad—hematologic cancer	0.00066	0.0214	CbGeAlD
Methamphetamine—SLC6A4—blood—hematologic cancer	0.000654	0.0212	CbGeAlD
Methamphetamine—SLC6A3—lung—hematologic cancer	0.000625	0.0203	CbGeAlD
Methamphetamine—MAOB—blood—hematologic cancer	0.000621	0.0201	CbGeAlD
Methamphetamine—ADRA2A—hematopoietic system—hematologic cancer	0.000614	0.0199	CbGeAlD
Methamphetamine—SLC6A3—testis—hematologic cancer	0.00059	0.0191	CbGeAlD
Methamphetamine—SLC22A3—lung—hematologic cancer	0.000589	0.0191	CbGeAlD
Methamphetamine—SLC6A4—lung—hematologic cancer	0.000573	0.0186	CbGeAlD
Methamphetamine—SLC18A2—lymph node—hematologic cancer	0.000565	0.0183	CbGeAlD
Methamphetamine—SLC22A3—testis—hematologic cancer	0.000555	0.018	CbGeAlD
Methamphetamine—MAOB—lung—hematologic cancer	0.000545	0.0176	CbGeAlD
Methamphetamine—MAOA—blood—hematologic cancer	0.00053	0.0172	CbGeAlD
Methamphetamine—MAOB—testis—hematologic cancer	0.000514	0.0166	CbGeAlD
Methamphetamine—ADRA2C—blood—hematologic cancer	0.00051	0.0165	CbGeAlD
Methamphetamine—SLC6A2—lung—hematologic cancer	0.000504	0.0163	CbGeAlD
Methamphetamine—SLC22A5—blood—hematologic cancer	0.000488	0.0158	CbGeAlD
Methamphetamine—SLC6A2—testis—hematologic cancer	0.000476	0.0154	CbGeAlD
Methamphetamine—CYP2D6—hematopoietic system—hematologic cancer	0.000476	0.0154	CbGeAlD
Methamphetamine—ADRA2A—gonad—hematologic cancer	0.000467	0.0151	CbGeAlD
Methamphetamine—MAOA—lung—hematologic cancer	0.000465	0.0151	CbGeAlD
Methamphetamine—ADRA2C—lung—hematologic cancer	0.000447	0.0145	CbGeAlD
Methamphetamine—MAOA—testis—hematologic cancer	0.000438	0.0142	CbGeAlD
Methamphetamine—SLC22A5—lung—hematologic cancer	0.000428	0.0139	CbGeAlD
Methamphetamine—ADRA2C—testis—hematologic cancer	0.000422	0.0137	CbGeAlD
Methamphetamine—ADRA2A—blood—hematologic cancer	0.000407	0.0132	CbGeAlD
Methamphetamine—Pseudoephedrine—IL2—hematologic cancer	0.000405	0.344	CrCbGaD
Methamphetamine—SLC22A5—testis—hematologic cancer	0.000404	0.0131	CbGeAlD
Methamphetamine—SLC22A3—lymph node—hematologic cancer	0.000403	0.013	CbGeAlD
Methamphetamine—MAOB—lymph node—hematologic cancer	0.000373	0.0121	CbGeAlD
Methamphetamine—ADRA2A—lung—hematologic cancer	0.000357	0.0115	CbGeAlD
Methamphetamine—SLC6A2—lymph node—hematologic cancer	0.000345	0.0112	CbGeAlD
Methamphetamine—ADRA2A—testis—hematologic cancer	0.000336	0.0109	CbGeAlD
Methamphetamine—MAOA—lymph node—hematologic cancer	0.000318	0.0103	CbGeAlD
Methamphetamine—CYP2D6—blood—hematologic cancer	0.000315	0.0102	CbGeAlD
Methamphetamine—ADRA2C—lymph node—hematologic cancer	0.000306	0.0099	CbGeAlD
Methamphetamine—Phenformin—SLC22A1—hematologic cancer	0.000293	0.249	CrCbGaD
Methamphetamine—SLC22A5—lymph node—hematologic cancer	0.000293	0.00948	CbGeAlD
Methamphetamine—CYP2D6—testis—hematologic cancer	0.000261	0.00844	CbGeAlD
Methamphetamine—ADRA2A—lymph node—hematologic cancer	0.000244	0.0079	CbGeAlD
Methamphetamine—Lacosamide—CA9—hematologic cancer	0.000238	0.202	CrCbGaD
Methamphetamine—Urticaria—Chlorambucil—hematologic cancer	0.00022	0.00225	CcSEcCtD
Methamphetamine—Agitation—Thalidomide—hematologic cancer	0.000219	0.00225	CcSEcCtD
Methamphetamine—Constipation—Vinblastine—hematologic cancer	0.000217	0.00222	CcSEcCtD
Methamphetamine—Hypersensitivity—Dasatinib—hematologic cancer	0.000216	0.00221	CcSEcCtD
Methamphetamine—Hypersensitivity—Bexarotene—hematologic cancer	0.000216	0.00221	CcSEcCtD
Methamphetamine—Hypersensitivity—Fludarabine—hematologic cancer	0.000215	0.00221	CcSEcCtD
Methamphetamine—Urticaria—Nilotinib—hematologic cancer	0.000215	0.00221	CcSEcCtD
Methamphetamine—Tremor—Carmustine—hematologic cancer	0.000214	0.0022	CcSEcCtD
Methamphetamine—Headache—Idarubicin—hematologic cancer	0.000214	0.0022	CcSEcCtD
Methamphetamine—Urticaria—Imatinib—hematologic cancer	0.000214	0.00219	CcSEcCtD
Methamphetamine—Tremor—Alitretinoin—hematologic cancer	0.000212	0.00218	CcSEcCtD
Methamphetamine—Dyspepsia—Melphalan—hematologic cancer	0.000212	0.00218	CcSEcCtD
Methamphetamine—Insomnia—Lenalidomide—hematologic cancer	0.000212	0.00218	CcSEcCtD
Methamphetamine—Palpitations—Thalidomide—hematologic cancer	0.000211	0.00216	CcSEcCtD
Methamphetamine—Diarrhoea—Busulfan—hematologic cancer	0.000211	0.00216	CcSEcCtD
Methamphetamine—Tachycardia—Bortezomib—hematologic cancer	0.00021	0.00216	CcSEcCtD
Methamphetamine—Agitation—Carmustine—hematologic cancer	0.00021	0.00216	CcSEcCtD
Methamphetamine—Urticaria—Cladribine—hematologic cancer	0.00021	0.00215	CcSEcCtD
Methamphetamine—Agitation—Alitretinoin—hematologic cancer	0.000208	0.00214	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Melphalan—hematologic cancer	0.000208	0.00214	CcSEcCtD
Methamphetamine—Headache—Teniposide—hematologic cancer	0.000208	0.00214	CcSEcCtD
Methamphetamine—Dyspepsia—Lenalidomide—hematologic cancer	0.000206	0.00212	CcSEcCtD
Methamphetamine—Agitation—Ifosfamide—hematologic cancer	0.000206	0.00211	CcSEcCtD
Methamphetamine—Psychotic disorder—Prednisone—hematologic cancer	0.000206	0.00211	CcSEcCtD
Methamphetamine—Tachycardia—Vinorelbine—hematologic cancer	0.000206	0.00211	CcSEcCtD
Methamphetamine—Diarrhoea—Procarbazine—hematologic cancer	0.000204	0.0021	CcSEcCtD
Methamphetamine—Hypersensitivity—Chlorambucil—hematologic cancer	0.000204	0.00209	CcSEcCtD
Methamphetamine—Dizziness—Busulfan—hematologic cancer	0.000204	0.00209	CcSEcCtD
Methamphetamine—Dyspepsia—Hydroxyurea—hematologic cancer	0.000203	0.00209	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Lenalidomide—hematologic cancer	0.000202	0.00208	CcSEcCtD
Methamphetamine—Agitation—Vincristine—hematologic cancer	0.000201	0.00206	CcSEcCtD
Methamphetamine—Constipation—Lenalidomide—hematologic cancer	0.0002	0.00206	CcSEcCtD
Methamphetamine—Palpitations—Alitretinoin—hematologic cancer	0.0002	0.00206	CcSEcCtD
Methamphetamine—Diarrhoea—Dasatinib—hematologic cancer	0.0002	0.00206	CcSEcCtD
Methamphetamine—Diarrhoea—Bexarotene—hematologic cancer	0.0002	0.00206	CcSEcCtD
Methamphetamine—Diarrhoea—Fludarabine—hematologic cancer	0.0002	0.00205	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Hydroxyurea—hematologic cancer	0.000199	0.00205	CcSEcCtD
Methamphetamine—Hypersensitivity—Nilotinib—hematologic cancer	0.000199	0.00205	CcSEcCtD
Methamphetamine—Hypersensitivity—Imatinib—hematologic cancer	0.000198	0.00203	CcSEcCtD
Methamphetamine—Palpitations—Ifosfamide—hematologic cancer	0.000198	0.00203	CcSEcCtD
Methamphetamine—Constipation—Hydroxyurea—hematologic cancer	0.000198	0.00203	CcSEcCtD
Methamphetamine—Dizziness—Procarbazine—hematologic cancer	0.000197	0.00203	CcSEcCtD
Methamphetamine—Tachycardia—Thiotepa—hematologic cancer	0.000196	0.00201	CcSEcCtD
Methamphetamine—Insomnia—Bortezomib—hematologic cancer	0.000195	0.002	CcSEcCtD
Methamphetamine—Hypersensitivity—Cladribine—hematologic cancer	0.000195	0.002	CcSEcCtD
Methamphetamine—Dizziness—Bexarotene—hematologic cancer	0.000194	0.00199	CcSEcCtD
Methamphetamine—Dizziness—Dasatinib—hematologic cancer	0.000194	0.00199	CcSEcCtD
Methamphetamine—Headache—Busulfan—hematologic cancer	0.000193	0.00198	CcSEcCtD
Methamphetamine—Urticaria—Melphalan—hematologic cancer	0.000191	0.00197	CcSEcCtD
Methamphetamine—Dyspepsia—Bortezomib—hematologic cancer	0.00019	0.00195	CcSEcCtD
Methamphetamine—Tachycardia—Thalidomide—hematologic cancer	0.00019	0.00195	CcSEcCtD
Methamphetamine—Diarrhoea—Chlorambucil—hematologic cancer	0.000189	0.00194	CcSEcCtD
Methamphetamine—Headache—Procarbazine—hematologic cancer	0.000187	0.00192	CcSEcCtD
Methamphetamine—Hypersensitivity—Vinblastine—hematologic cancer	0.000187	0.00192	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Bortezomib—hematologic cancer	0.000186	0.00191	CcSEcCtD
Methamphetamine—Urticaria—Lenalidomide—hematologic cancer	0.000186	0.00191	CcSEcCtD
Methamphetamine—Diarrhoea—Nilotinib—hematologic cancer	0.000185	0.0019	CcSEcCtD
Methamphetamine—Constipation—Bortezomib—hematologic cancer	0.000184	0.00189	CcSEcCtD
Methamphetamine—Diarrhoea—Imatinib—hematologic cancer	0.000184	0.00189	CcSEcCtD
Methamphetamine—Headache—Dasatinib—hematologic cancer	0.000183	0.00188	CcSEcCtD
Methamphetamine—Headache—Bexarotene—hematologic cancer	0.000183	0.00188	CcSEcCtD
Methamphetamine—Headache—Fludarabine—hematologic cancer	0.000183	0.00188	CcSEcCtD
Methamphetamine—Tachycardia—Carmustine—hematologic cancer	0.000182	0.00187	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Vinorelbine—hematologic cancer	0.000182	0.00187	CcSEcCtD
Methamphetamine—Tremor—Cisplatin—hematologic cancer	0.000181	0.00186	CcSEcCtD
Methamphetamine—Diarrhoea—Cladribine—hematologic cancer	0.000181	0.00186	CcSEcCtD
Methamphetamine—Tachycardia—Alitretinoin—hematologic cancer	0.000181	0.00185	CcSEcCtD
Methamphetamine—Constipation—Vinorelbine—hematologic cancer	0.00018	0.00185	CcSEcCtD
Methamphetamine—Dizziness—Nilotinib—hematologic cancer	0.000179	0.00184	CcSEcCtD
Methamphetamine—Dizziness—Imatinib—hematologic cancer	0.000178	0.00183	CcSEcCtD
Methamphetamine—Hypersensitivity—Melphalan—hematologic cancer	0.000178	0.00182	CcSEcCtD
Methamphetamine—Dyspepsia—Thiotepa—hematologic cancer	0.000177	0.00182	CcSEcCtD
Methamphetamine—Insomnia—Thalidomide—hematologic cancer	0.000176	0.00181	CcSEcCtD
Methamphetamine—Dizziness—Cladribine—hematologic cancer	0.000175	0.00179	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Thiotepa—hematologic cancer	0.000174	0.00178	CcSEcCtD
Methamphetamine—Diarrhoea—Vinblastine—hematologic cancer	0.000173	0.00178	CcSEcCtD
Methamphetamine—Hypersensitivity—Lenalidomide—hematologic cancer	0.000173	0.00177	CcSEcCtD
Methamphetamine—Constipation—Thiotepa—hematologic cancer	0.000172	0.00177	CcSEcCtD
Methamphetamine—Urticaria—Bortezomib—hematologic cancer	0.000171	0.00176	CcSEcCtD
Methamphetamine—Dyspepsia—Thalidomide—hematologic cancer	0.000171	0.00176	CcSEcCtD
Methamphetamine—Hypersensitivity—Hydroxyurea—hematologic cancer	0.00017	0.00175	CcSEcCtD
Methamphetamine—Urticaria—Bleomycin—hematologic cancer	0.00017	0.00175	CcSEcCtD
Methamphetamine—Tachycardia—Mitoxantrone—hematologic cancer	0.000169	0.00174	CcSEcCtD
Methamphetamine—Headache—Nilotinib—hematologic cancer	0.000169	0.00174	CcSEcCtD
Methamphetamine—Insomnia—Carmustine—hematologic cancer	0.000169	0.00173	CcSEcCtD
Methamphetamine—Headache—Imatinib—hematologic cancer	0.000168	0.00173	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Thalidomide—hematologic cancer	0.000168	0.00172	CcSEcCtD
Methamphetamine—Erectile dysfunction—Prednisone—hematologic cancer	0.000168	0.00172	CcSEcCtD
Methamphetamine—Dizziness—Vinblastine—hematologic cancer	0.000168	0.00172	CcSEcCtD
Methamphetamine—Insomnia—Alitretinoin—hematologic cancer	0.000167	0.00172	CcSEcCtD
Methamphetamine—Urticaria—Vinorelbine—hematologic cancer	0.000167	0.00172	CcSEcCtD
Methamphetamine—Constipation—Thalidomide—hematologic cancer	0.000166	0.00171	CcSEcCtD
Methamphetamine—Headache—Cladribine—hematologic cancer	0.000166	0.0017	CcSEcCtD
Methamphetamine—Diarrhoea—Melphalan—hematologic cancer	0.000165	0.00169	CcSEcCtD
Methamphetamine—Dyspepsia—Alitretinoin—hematologic cancer	0.000163	0.00167	CcSEcCtD
Methamphetamine—Insomnia—Vincristine—hematologic cancer	0.000161	0.00166	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Carmustine—hematologic cancer	0.000161	0.00166	CcSEcCtD
Methamphetamine—Diarrhoea—Lenalidomide—hematologic cancer	0.00016	0.00165	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.00016	0.00164	CcSEcCtD
Methamphetamine—Urticaria—Thiotepa—hematologic cancer	0.00016	0.00164	CcSEcCtD
Methamphetamine—Constipation—Carmustine—hematologic cancer	0.00016	0.00164	CcSEcCtD
Methamphetamine—Hypersensitivity—Bortezomib—hematologic cancer	0.000159	0.00163	CcSEcCtD
Methamphetamine—Headache—Vinblastine—hematologic cancer	0.000159	0.00163	CcSEcCtD
Methamphetamine—Constipation—Alitretinoin—hematologic cancer	0.000158	0.00162	CcSEcCtD
Methamphetamine—Diarrhoea—Hydroxyurea—hematologic cancer	0.000158	0.00162	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000158	0.00162	CcSEcCtD
Methamphetamine—Hypersensitivity—Bleomycin—hematologic cancer	0.000158	0.00162	CcSEcCtD
Methamphetamine—Insomnia—Irinotecan—hematologic cancer	0.000157	0.00161	CcSEcCtD
Methamphetamine—Constipation—Ifosfamide—hematologic cancer	0.000156	0.00161	CcSEcCtD
Methamphetamine—Hypersensitivity—Vinorelbine—hematologic cancer	0.000155	0.00159	CcSEcCtD
Methamphetamine—Dizziness—Lenalidomide—hematologic cancer	0.000155	0.00159	CcSEcCtD
Methamphetamine—Urticaria—Thalidomide—hematologic cancer	0.000155	0.00159	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000154	0.00158	CcSEcCtD
Methamphetamine—Tachycardia—Cisplatin—hematologic cancer	0.000154	0.00158	CcSEcCtD
Methamphetamine—Insomnia—Gemcitabine—hematologic cancer	0.000153	0.00157	CcSEcCtD
Methamphetamine—Dyspepsia—Mitoxantrone—hematologic cancer	0.000153	0.00157	CcSEcCtD
Methamphetamine—Dyspepsia—Irinotecan—hematologic cancer	0.000153	0.00157	CcSEcCtD
Methamphetamine—Dizziness—Hydroxyurea—hematologic cancer	0.000153	0.00157	CcSEcCtD
Methamphetamine—Constipation—Vincristine—hematologic cancer	0.000152	0.00157	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.00015	0.00154	CcSEcCtD
Methamphetamine—Constipation—Mitoxantrone—hematologic cancer	0.000149	0.00152	CcSEcCtD
Methamphetamine—Constipation—Irinotecan—hematologic cancer	0.000149	0.00152	CcSEcCtD
Methamphetamine—Hypersensitivity—Thiotepa—hematologic cancer	0.000148	0.00152	CcSEcCtD
Methamphetamine—Diarrhoea—Bortezomib—hematologic cancer	0.000148	0.00151	CcSEcCtD
Methamphetamine—Urticaria—Alitretinoin—hematologic cancer	0.000147	0.00151	CcSEcCtD
Methamphetamine—Headache—Lenalidomide—hematologic cancer	0.000147	0.00151	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000146	0.0015	CcSEcCtD
Methamphetamine—Urticaria—Ifosfamide—hematologic cancer	0.000145	0.00149	CcSEcCtD
Methamphetamine—Headache—Hydroxyurea—hematologic cancer	0.000145	0.00149	CcSEcCtD
Methamphetamine—Constipation—Gemcitabine—hematologic cancer	0.000145	0.00148	CcSEcCtD
Methamphetamine—Diarrhoea—Vinorelbine—hematologic cancer	0.000144	0.00148	CcSEcCtD
Methamphetamine—Hypersensitivity—Thalidomide—hematologic cancer	0.000143	0.00147	CcSEcCtD
Methamphetamine—Dizziness—Bortezomib—hematologic cancer	0.000143	0.00146	CcSEcCtD
Methamphetamine—Tachycardia—Etoposide—hematologic cancer	0.000141	0.00145	CcSEcCtD
Methamphetamine—Erectile dysfunction—Methotrexate—hematologic cancer	0.00014	0.00144	CcSEcCtD
Methamphetamine—Dizziness—Vinorelbine—hematologic cancer	0.000139	0.00143	CcSEcCtD
Methamphetamine—Tachycardia—Prednisolone—hematologic cancer	0.000139	0.00143	CcSEcCtD
Methamphetamine—Urticaria—Mitoxantrone—hematologic cancer	0.000138	0.00142	CcSEcCtD
Methamphetamine—Hypersensitivity—Carmustine—hematologic cancer	0.000138	0.00141	CcSEcCtD
Methamphetamine—Diarrhoea—Thiotepa—hematologic cancer	0.000138	0.00141	CcSEcCtD
Methamphetamine—Pseudoephedrine—TNF—hematologic cancer	0.000137	0.116	CrCbGaD
Methamphetamine—Hypersensitivity—Alitretinoin—hematologic cancer	0.000136	0.0014	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000136	0.0014	CcSEcCtD
Methamphetamine—Headache—Bortezomib—hematologic cancer	0.000135	0.00139	CcSEcCtD
Methamphetamine—Hypersensitivity—Ifosfamide—hematologic cancer	0.000135	0.00138	CcSEcCtD
Methamphetamine—Diarrhoea—Thalidomide—hematologic cancer	0.000133	0.00137	CcSEcCtD
Methamphetamine—Dizziness—Thiotepa—hematologic cancer	0.000133	0.00137	CcSEcCtD
Methamphetamine—Headache—Vinorelbine—hematologic cancer	0.000132	0.00135	CcSEcCtD
Methamphetamine—Hypersensitivity—Vincristine—hematologic cancer	0.000131	0.00135	CcSEcCtD
Methamphetamine—Insomnia—Prednisolone—hematologic cancer	0.000129	0.00132	CcSEcCtD
Methamphetamine—Dizziness—Thalidomide—hematologic cancer	0.000129	0.00132	CcSEcCtD
Methamphetamine—Hypersensitivity—Irinotecan—hematologic cancer	0.000128	0.00131	CcSEcCtD
Methamphetamine—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000128	0.00131	CcSEcCtD
Methamphetamine—Tachycardia—Triamcinolone—hematologic cancer	0.000128	0.00131	CcSEcCtD
Methamphetamine—Diarrhoea—Carmustine—hematologic cancer	0.000128	0.00131	CcSEcCtD
Methamphetamine—Diarrhoea—Alitretinoin—hematologic cancer	0.000127	0.0013	CcSEcCtD
Methamphetamine—Headache—Thiotepa—hematologic cancer	0.000126	0.00129	CcSEcCtD
Methamphetamine—Diarrhoea—Ifosfamide—hematologic cancer	0.000125	0.00128	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000125	0.00128	CcSEcCtD
Methamphetamine—Dizziness—Carmustine—hematologic cancer	0.000124	0.00127	CcSEcCtD
Methamphetamine—Constipation—Etoposide—hematologic cancer	0.000124	0.00127	CcSEcCtD
Methamphetamine—Dizziness—Alitretinoin—hematologic cancer	0.000122	0.00126	CcSEcCtD
Methamphetamine—Diarrhoea—Vincristine—hematologic cancer	0.000122	0.00125	CcSEcCtD
Methamphetamine—Headache—Thalidomide—hematologic cancer	0.000122	0.00125	CcSEcCtD
Methamphetamine—Dizziness—Ifosfamide—hematologic cancer	0.000121	0.00124	CcSEcCtD
Methamphetamine—Diarrhoea—Mitoxantrone—hematologic cancer	0.000119	0.00122	CcSEcCtD
Methamphetamine—Diarrhoea—Irinotecan—hematologic cancer	0.000119	0.00122	CcSEcCtD
Methamphetamine—Insomnia—Triamcinolone—hematologic cancer	0.000119	0.00122	CcSEcCtD
Methamphetamine—Dizziness—Vincristine—hematologic cancer	0.000118	0.00121	CcSEcCtD
Methamphetamine—Headache—Carmustine—hematologic cancer	0.000117	0.0012	CcSEcCtD
Methamphetamine—Agitation—Prednisone—hematologic cancer	0.000117	0.0012	CcSEcCtD
Methamphetamine—Hypersensitivity—Cisplatin—hematologic cancer	0.000116	0.00119	CcSEcCtD
Methamphetamine—Tachycardia—Betamethasone—hematologic cancer	0.000116	0.00119	CcSEcCtD
Methamphetamine—Tachycardia—Dexamethasone—hematologic cancer	0.000116	0.00119	CcSEcCtD
Methamphetamine—Headache—Alitretinoin—hematologic cancer	0.000116	0.00119	CcSEcCtD
Methamphetamine—Diarrhoea—Gemcitabine—hematologic cancer	0.000116	0.00119	CcSEcCtD
Methamphetamine—Dyspepsia—Triamcinolone—hematologic cancer	0.000115	0.00118	CcSEcCtD
Methamphetamine—Dizziness—Irinotecan—hematologic cancer	0.000115	0.00118	CcSEcCtD
Methamphetamine—Urticaria—Etoposide—hematologic cancer	0.000115	0.00118	CcSEcCtD
Methamphetamine—Urticaria—Prednisolone—hematologic cancer	0.000113	0.00116	CcSEcCtD
Methamphetamine—Headache—Vincristine—hematologic cancer	0.000112	0.00115	CcSEcCtD
Methamphetamine—Headache—Irinotecan—hematologic cancer	0.000109	0.00112	CcSEcCtD
Methamphetamine—Headache—Mitoxantrone—hematologic cancer	0.000109	0.00112	CcSEcCtD
Methamphetamine—Diarrhoea—Cisplatin—hematologic cancer	0.000108	0.00111	CcSEcCtD
Methamphetamine—Insomnia—Dexamethasone—hematologic cancer	0.000108	0.0011	CcSEcCtD
Methamphetamine—Insomnia—Betamethasone—hematologic cancer	0.000108	0.0011	CcSEcCtD
Methamphetamine—Hypersensitivity—Etoposide—hematologic cancer	0.000106	0.00109	CcSEcCtD
Methamphetamine—Headache—Gemcitabine—hematologic cancer	0.000106	0.00109	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisolone—hematologic cancer	0.000105	0.00108	CcSEcCtD
Methamphetamine—Dyspepsia—Dexamethasone—hematologic cancer	0.000105	0.00107	CcSEcCtD
Methamphetamine—Dyspepsia—Betamethasone—hematologic cancer	0.000105	0.00107	CcSEcCtD
Methamphetamine—Urticaria—Triamcinolone—hematologic cancer	0.000104	0.00107	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000103	0.00105	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000103	0.00105	CcSEcCtD
Methamphetamine—Tachycardia—Prednisone—hematologic cancer	0.000101	0.00104	CcSEcCtD
Methamphetamine—Diarrhoea—Etoposide—hematologic cancer	9.88e-05	0.00101	CcSEcCtD
Methamphetamine—Hypersensitivity—Triamcinolone—hematologic cancer	9.65e-05	0.000991	CcSEcCtD
Methamphetamine—Dizziness—Etoposide—hematologic cancer	9.55e-05	0.000981	CcSEcCtD
Methamphetamine—Urticaria—Dexamethasone—hematologic cancer	9.44e-05	0.000969	CcSEcCtD
Methamphetamine—Urticaria—Betamethasone—hematologic cancer	9.44e-05	0.000969	CcSEcCtD
Methamphetamine—Dizziness—Prednisolone—hematologic cancer	9.42e-05	0.000967	CcSEcCtD
Methamphetamine—Insomnia—Prednisone—hematologic cancer	9.36e-05	0.000961	CcSEcCtD
Methamphetamine—Agitation—Epirubicin—hematologic cancer	9.12e-05	0.000936	CcSEcCtD
Methamphetamine—Dyspepsia—Prednisone—hematologic cancer	9.11e-05	0.000936	CcSEcCtD
Methamphetamine—Headache—Etoposide—hematologic cancer	9.05e-05	0.000929	CcSEcCtD
Methamphetamine—Headache—Prednisolone—hematologic cancer	8.93e-05	0.000916	CcSEcCtD
Methamphetamine—Constipation—Prednisone—hematologic cancer	8.85e-05	0.000909	CcSEcCtD
Methamphetamine—Palpitations—Epirubicin—hematologic cancer	8.77e-05	0.0009	CcSEcCtD
Methamphetamine—Dizziness—Triamcinolone—hematologic cancer	8.66e-05	0.000889	CcSEcCtD
Methamphetamine—Agitation—Doxorubicin—hematologic cancer	8.44e-05	0.000866	CcSEcCtD
Methamphetamine—Urticaria—Prednisone—hematologic cancer	8.22e-05	0.000844	CcSEcCtD
Methamphetamine—Headache—Triamcinolone—hematologic cancer	8.21e-05	0.000843	CcSEcCtD
Methamphetamine—Diarrhoea—Betamethasone—hematologic cancer	8.13e-05	0.000835	CcSEcCtD
Methamphetamine—Diarrhoea—Dexamethasone—hematologic cancer	8.13e-05	0.000835	CcSEcCtD
Methamphetamine—Palpitations—Doxorubicin—hematologic cancer	8.11e-05	0.000833	CcSEcCtD
Methamphetamine—Tachycardia—Epirubicin—hematologic cancer	7.9e-05	0.000811	CcSEcCtD
Methamphetamine—Dizziness—Dexamethasone—hematologic cancer	7.86e-05	0.000807	CcSEcCtD
Methamphetamine—Dizziness—Betamethasone—hematologic cancer	7.86e-05	0.000807	CcSEcCtD
Methamphetamine—Insomnia—Methotrexate—hematologic cancer	7.83e-05	0.000803	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisone—hematologic cancer	7.63e-05	0.000783	CcSEcCtD
Methamphetamine—Dyspepsia—Methotrexate—hematologic cancer	7.62e-05	0.000782	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.47e-05	0.000767	CcSEcCtD
Methamphetamine—Headache—Betamethasone—hematologic cancer	7.45e-05	0.000765	CcSEcCtD
Methamphetamine—Headache—Dexamethasone—hematologic cancer	7.45e-05	0.000765	CcSEcCtD
Methamphetamine—Insomnia—Epirubicin—hematologic cancer	7.32e-05	0.000752	CcSEcCtD
Methamphetamine—Tachycardia—Doxorubicin—hematologic cancer	7.31e-05	0.000751	CcSEcCtD
Methamphetamine—Dyspepsia—Epirubicin—hematologic cancer	7.13e-05	0.000732	CcSEcCtD
Methamphetamine—Diarrhoea—Prednisone—hematologic cancer	7.08e-05	0.000727	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.99e-05	0.000718	CcSEcCtD
Methamphetamine—Constipation—Epirubicin—hematologic cancer	6.92e-05	0.000711	CcSEcCtD
Methamphetamine—Urticaria—Methotrexate—hematologic cancer	6.87e-05	0.000706	CcSEcCtD
Methamphetamine—Dizziness—Prednisone—hematologic cancer	6.85e-05	0.000703	CcSEcCtD
Methamphetamine—Insomnia—Doxorubicin—hematologic cancer	6.78e-05	0.000696	CcSEcCtD
Methamphetamine—Dyspepsia—Doxorubicin—hematologic cancer	6.59e-05	0.000677	CcSEcCtD
Methamphetamine—Headache—Prednisone—hematologic cancer	6.49e-05	0.000666	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.47e-05	0.000664	CcSEcCtD
Methamphetamine—Urticaria—Epirubicin—hematologic cancer	6.43e-05	0.00066	CcSEcCtD
Methamphetamine—Constipation—Doxorubicin—hematologic cancer	6.41e-05	0.000658	CcSEcCtD
Methamphetamine—Hypersensitivity—Methotrexate—hematologic cancer	6.37e-05	0.000654	CcSEcCtD
Methamphetamine—Hypersensitivity—Epirubicin—hematologic cancer	5.97e-05	0.000612	CcSEcCtD
Methamphetamine—Urticaria—Doxorubicin—hematologic cancer	5.95e-05	0.000611	CcSEcCtD
Methamphetamine—Diarrhoea—Methotrexate—hematologic cancer	5.92e-05	0.000608	CcSEcCtD
Methamphetamine—Dizziness—Methotrexate—hematologic cancer	5.72e-05	0.000587	CcSEcCtD
Methamphetamine—Diarrhoea—Epirubicin—hematologic cancer	5.54e-05	0.000569	CcSEcCtD
Methamphetamine—Hypersensitivity—Doxorubicin—hematologic cancer	5.52e-05	0.000567	CcSEcCtD
Methamphetamine—Headache—Methotrexate—hematologic cancer	5.42e-05	0.000556	CcSEcCtD
Methamphetamine—Selegiline—ABCB1—hematologic cancer	5.39e-05	0.0458	CrCbGaD
Methamphetamine—Dizziness—Epirubicin—hematologic cancer	5.35e-05	0.00055	CcSEcCtD
Methamphetamine—Diarrhoea—Doxorubicin—hematologic cancer	5.13e-05	0.000526	CcSEcCtD
Methamphetamine—Headache—Epirubicin—hematologic cancer	5.07e-05	0.000521	CcSEcCtD
Methamphetamine—Nateglinide—ALB—hematologic cancer	5.05e-05	0.0429	CrCbGaD
Methamphetamine—Dizziness—Doxorubicin—hematologic cancer	4.95e-05	0.000509	CcSEcCtD
Methamphetamine—Headache—Doxorubicin—hematologic cancer	4.69e-05	0.000482	CcSEcCtD
Methamphetamine—ADRA2A—Signaling Pathways—PDGFA—hematologic cancer	3.65e-06	4.21e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3R1—hematologic cancer	3.65e-06	4.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT1—hematologic cancer	3.64e-06	4.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2RA—hematologic cancer	3.63e-06	4.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CG—hematologic cancer	3.61e-06	4.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—hematologic cancer	3.6e-06	4.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KITLG—hematologic cancer	3.6e-06	4.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TERT—hematologic cancer	3.59e-06	4.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGFR3—hematologic cancer	3.52e-06	4.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT5A—hematologic cancer	3.52e-06	4.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	3.51e-06	4.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PDGFB—hematologic cancer	3.5e-06	4.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—hematologic cancer	3.49e-06	4.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK14—hematologic cancer	3.49e-06	4.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN2B—hematologic cancer	3.49e-06	4.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3R1—hematologic cancer	3.45e-06	3.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ESR1—hematologic cancer	3.42e-06	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TSC2—hematologic cancer	3.42e-06	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—hematologic cancer	3.4e-06	3.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PIK3CA—hematologic cancer	3.38e-06	3.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FN1—hematologic cancer	3.38e-06	3.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CD86—hematologic cancer	3.37e-06	3.89e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CB—hematologic cancer	3.37e-06	3.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NQO1—hematologic cancer	3.36e-06	3.88e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CD44—hematologic cancer	3.36e-06	3.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—JAK2—hematologic cancer	3.35e-06	3.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CREBBP—hematologic cancer	3.35e-06	3.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKBIA—hematologic cancer	3.34e-06	3.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—BAD—hematologic cancer	3.34e-06	3.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HES1—hematologic cancer	3.32e-06	3.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOTCH1—hematologic cancer	3.31e-06	3.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NCOR1—hematologic cancer	3.31e-06	3.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGFR3—hematologic cancer	3.29e-06	3.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—hematologic cancer	3.27e-06	3.78e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CA—hematologic cancer	3.27e-06	3.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	3.27e-06	3.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CSF2—hematologic cancer	3.27e-06	3.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK14—hematologic cancer	3.26e-06	3.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CD80—hematologic cancer	3.24e-06	3.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	3.24e-06	3.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KIT—hematologic cancer	3.24e-06	3.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	3.24e-06	3.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	3.22e-06	3.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	3.22e-06	3.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	3.22e-06	3.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ESR1—hematologic cancer	3.2e-06	3.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	3.18e-06	3.68e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYCS—hematologic cancer	3.18e-06	3.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	3.18e-06	3.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CD—hematologic cancer	3.18e-06	3.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	3.17e-06	3.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	3.16e-06	3.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FN1—hematologic cancer	3.16e-06	3.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	3.16e-06	3.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	3.16e-06	3.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—hematologic cancer	3.14e-06	3.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HRAS—hematologic cancer	3.13e-06	3.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—BAD—hematologic cancer	3.12e-06	3.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKBIA—hematologic cancer	3.12e-06	3.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	3.1e-06	3.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOTCH1—hematologic cancer	3.09e-06	3.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	3.08e-06	3.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	3.04e-06	3.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CD80—hematologic cancer	3.03e-06	3.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CG—hematologic cancer	3.02e-06	3.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KIT—hematologic cancer	3.02e-06	3.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—NRAS—hematologic cancer	3.02e-06	3.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	3.01e-06	3.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	3e-06	3.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3R1—hematologic cancer	3e-06	3.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	3e-06	3.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTPN11—hematologic cancer	2.97e-06	3.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	2.95e-06	3.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CG—hematologic cancer	2.94e-06	3.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	2.92e-06	3.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—hematologic cancer	2.91e-06	3.36e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTEN—hematologic cancer	2.91e-06	3.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—MAPK3—hematologic cancer	2.89e-06	3.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CREB1—hematologic cancer	2.88e-06	3.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	2.86e-06	3.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	2.84e-06	3.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	2.84e-06	3.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—BRAF—hematologic cancer	2.84e-06	3.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	2.82e-06	3.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL2—hematologic cancer	2.81e-06	3.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6R—hematologic cancer	2.81e-06	3.24e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.8e-06	3.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CREBBP—hematologic cancer	2.8e-06	3.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	2.78e-06	3.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	2.78e-06	3.21e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—EP300—hematologic cancer	2.77e-06	3.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CB—hematologic cancer	2.77e-06	3.2e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CA—hematologic cancer	2.77e-06	3.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—hematologic cancer	2.76e-06	3.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	2.72e-06	3.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CREBBP—hematologic cancer	2.72e-06	3.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	2.69e-06	3.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	2.67e-06	3.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	2.67e-06	3.09e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—hematologic cancer	2.67e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	2.66e-06	3.07e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.65e-06	3.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	2.65e-06	3.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	2.63e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	2.61e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	2.6e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	2.6e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	2.58e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.58e-06	2.97e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.58e-06	2.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	2.57e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	2.56e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	2.55e-06	2.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—hematologic cancer	2.55e-06	2.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	2.54e-06	2.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	2.53e-06	2.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	2.53e-06	2.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	2.51e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	2.51e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	2.48e-06	2.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	2.48e-06	2.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	2.46e-06	2.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	2.45e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	2.45e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	2.45e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	2.44e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	2.44e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	2.41e-06	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTEN—hematologic cancer	2.39e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	2.39e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	2.38e-06	2.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	2.37e-06	2.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	2.35e-06	2.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	2.34e-06	2.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	2.33e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	2.32e-06	2.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	2.32e-06	2.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	2.31e-06	2.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	2.3e-06	2.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	2.29e-06	2.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—EP300—hematologic cancer	2.28e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	2.28e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	2.28e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.28e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—hematologic cancer	2.28e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	2.28e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	2.27e-06	2.62e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—hematologic cancer	2.26e-06	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	2.25e-06	2.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	2.22e-06	2.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JUN—hematologic cancer	2.21e-06	2.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	2.21e-06	2.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	2.17e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	2.17e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	2.16e-06	2.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	2.15e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	2.15e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	2.14e-06	2.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.14e-06	2.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	2.13e-06	2.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—hematologic cancer	2.13e-06	2.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	2.12e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	2.11e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	2.1e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	2.09e-06	2.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	2.07e-06	2.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JUN—hematologic cancer	2.07e-06	2.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	2.07e-06	2.39e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CA—hematologic cancer	2.05e-06	2.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	2.04e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	2.04e-06	2.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	2.01e-06	2.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	2e-06	2.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	1.99e-06	2.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	1.98e-06	2.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	1.96e-06	2.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	1.95e-06	2.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTEN—hematologic cancer	1.94e-06	2.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.94e-06	2.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	1.93e-06	2.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	1.93e-06	2.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	1.92e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.91e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	1.91e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EP300—hematologic cancer	1.91e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	1.88e-06	2.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.88e-06	2.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	1.86e-06	2.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—EP300—hematologic cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	1.83e-06	2.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	1.81e-06	2.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	1.8e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	1.79e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	1.79e-06	2.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	1.78e-06	2.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	1.78e-06	2.05e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.77e-06	2.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.77e-06	2.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.75e-06	2.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.73e-06	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.73e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.72e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.71e-06	1.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.69e-06	1.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.68e-06	1.94e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.68e-06	1.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.68e-06	1.94e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—hematologic cancer	1.68e-06	1.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.66e-06	1.92e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—hematologic cancer	1.66e-06	1.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.66e-06	1.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.64e-06	1.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.63e-06	1.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.63e-06	1.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.59e-06	1.84e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.59e-06	1.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.59e-06	1.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.55e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.54e-06	1.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.51e-06	1.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.51e-06	1.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.47e-06	1.69e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.47e-06	1.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.46e-06	1.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.45e-06	1.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.45e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1.41e-06	1.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.4e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.39e-06	1.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—hematologic cancer	1.38e-06	1.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.37e-06	1.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.37e-06	1.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.35e-06	1.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.35e-06	1.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.34e-06	1.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.31e-06	1.51e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.27e-06	1.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.25e-06	1.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.25e-06	1.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.23e-06	1.43e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—EP300—hematologic cancer	1.21e-06	1.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.15e-06	1.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.15e-06	1.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—hematologic cancer	1.12e-06	1.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.11e-06	1.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.06e-06	1.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.02e-06	1.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	9.37e-07	1.08e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.94e-07	1.03e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—hematologic cancer	7.3e-07	8.43e-06	CbGpPWpGaD
